logo-loader
ImmuPharma PLC

Immupharma PLC - IMMUPHARMA AT BIO-EQUITY 2024 12-14 May

RNS Number : 7666L
Immupharma PLC
24 April 2024
 

 

RNS REACH | 24 April 2024

 

ImmuPharma PLC

("ImmuPharma" or the "Company") 

 

IMMUPHARMA AT BIO-EQUITY 2024

12-14 May 2024, SAN SEBASTIAN

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Equity. The event will be held from 12-14 May 2024, in San Sebastian, Spain.

BIO-Equity is an annual premier partnering event, designed to provide biotechnology companies with the opportunity to present to and connect with investors together with the global biopharma community. This event provides an important continuum for ImmuPharma to facilitate ongoing discussions regarding potential global partnering deals across its pipeline portfolio. 

Commenting on the event, Tim McCarthy, CEO of ImmuPharma said: "Further to our clinical progress with P140 in SLE and CIDP, attending BIO-Equity 2024 offers the opportunity to continue discussions on our unique portfolio with specific bioPharma companies and investment specialists, particularly in relation to SLE, CIDP and potentially other autoimmune diseases within our P140 technology platform. Our focus remains on track to establish global partnering opportunities across all our programs."

 

For further information please contact: 

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 



 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 650 3650

 

 

+44 (0) 1483 413500



Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About Lupus (Systemic Lupus Erythematosus / SLE)

 

Lupus is a chronic inflammatory disease which is thought to affect some 16 million individuals worldwide. The current standard of care still consists of steroid and anti-malarial therapies which many have side-effects and poor response in many patients. Recently more targeted monoclonal therapies are GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There still exists a high unmet medical need for a drug that has a strong efficacy and safety profile.

 

About CIDP (Chronic Idiopathic Demyelinating Polyneuropathy)

 

CIDP is a rare acquired autoimmune disorder of peripheral nerves which is thought to affect some 90 thousand individuals across US/Europe.  It is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. CIDP related disability may be substantial. In addition to the physical burdens imposed by the disease, those affected by CIDP also frequently experience economic and emotional hardship and are often burdened not only by the disease but also by the immunotherapies used to treat the disease. Other than intravenous (IVIG) and subcutaneous immunoglobulin (SCIG), corticosteroids and plasma exchange are the only other treatment options. There is still a huge unmet need for more efficacious drugs that are safer, and which affect underlying disease progression.

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFITSFIVFIS
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Seeing Machines, Frontier IP, ImmuPharma, MP Evans, Ariana Resources, 88...

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z) has won a new driver monitoring contract with a European carmaker worth around $5 million in lifetime revenue, just as new EU safety rules make the technology mandatory on new vehicles. Production starts in 2028, with the system built into a...

on 07/22/2026

4 min read